
- Applied Clinical Trials-02-01-2016
- Volume 25
- Issue 2
Competitive Pressure for First-in-Class Drugs is Intensifying
Study shows sharp reduction in market exclusivity periods for first-in-class treatment entrants.
Competition between drugs within a given class has intensified, according to a new study recently published by the Tufts Center for the Study of Drug Development (Tufts CSDD). Newly approved first-in-class prescription drugs face substantially shorter periods of exclusivity within which to recoup the high and rising cost of drug development.
Tufts CSDD reviewed 40 multiple-entrant pharmacologic classes that produced 108 new drug approvals in which the first-in-class agent received approval between 1998 and 2011. Comparing market exclusivity periods for drugs approved between 1998-2004 and those approved between 2005-2011, the results show a 51% reduction in the median time-from 4.7 years down to 2.3 years-from when the first-in-class drug was approved to when the first competitor entered the market. Three-out-of-four second entrants in a given drug class were approved within 3.7 years and 25% were approved in less than six months. Tufts CSDD also found that nearly half (49%) of the 40 classes examined eventually had three or more competitors.
Articles in this issue
over 9 years ago
EMA Adopts New Strategy on Measuring Impact of Pharmacovigilanceover 9 years ago
Ambition vs. Assessment: The Approval-Reimbursement Divideover 9 years ago
How Do You View the Future of Wearables?over 9 years ago
What Google Can Teach Us About Trial Education, Awarenessover 9 years ago
Preventing Patient Centricity from Becoming a Fadover 9 years ago
Clinical Trial Knowledge Missed, Gained, and Sharedover 9 years ago
Investigator Characteristics & Patient Recruitment in ALLHATover 9 years ago
Barriers to Trial Recruitment and Possible SolutionsNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.